It is a pleasure to answer and explain the three requests mentioned in your letter to the editor [1]:
1. Our study [2] should describe a practical tool not only for diagnosis, but also for preoperative planning and decision making of coronary bypass grafting. We adopted and modified the classical segment model of the American Heart Association. This coronary tree model is mainly designed for diagnosis of any coronary disease from a cardiologist's perspective. We still used segments, but we differentiated these sections more from a cardiac-surgical perspective. Definitely, this is discussable; however, we believe that we assess invasive coronary angiographies (ICA) on different aspects compared with cardiologists. Of course, this modification is an individual classification from our clinic and can also be used in a classical way. However, it should demonstrate that it is timely and necessary to assess imaging in the cardiac-surgical perspective, which can differ from others because the goals are different. 2. Of course, we used existing protocols, neither had we reprogrammed the software and/or developed new hardware, nor have we changed the contents of the protocols themselves. The modifications and new features were the application and composition of soft-and hardware, respectively, the different parts of the imaging tools and techniques. In addition, the definition of arrangements of responsibilities and manpower is important. Radiologists are responsible for optimal image quality for diagnostic, but cannot decide how many coronary bypass grafts are necessary and where they should be placed on the heart. This decision can only be done by cardiac surgeons. Because of that, they have to be able to use at least the basic steps at an original workstation to define the strategy themselves. This cannot be done based on images of radiologists because the purpose of these images is different. Especially, cardiac surgeons need three-dimensional (3D) images for overview of the topography and orientation to plan a potential surgical procedure, which is not possible in 2D images. 3. We believe it is important to 'keep it simple', so that transfer to clinical routine is easier to accomplish. The quantification of degree of stenosis was performed in the ICA in different views such as those commonly used in clinical routine. The diameter measurements in computed tomography (CT) were performed with an electronic calliper tool.
It is now the responsibility of cardiac surgeons to use CTas a diagnostic and planning tool instead of ICA. Our article should be an alert and encouragement to proceed. However, we also realised the problem of a certain inhibition threshold. Cardiac surgeons receive the prepared images by radiologists, which are definitely not optimal to prepare surgery. On the other hand, they do not have the time and practice to professionally use the workstation of a CT scanner. Our article illustrates one possibility to differentiate the work between radiologists and cardiac surgeons. Cardiac surgeons should be at least able to perform by themselves the steps which are described in this article. Otherwise, it will not be possible to transfer CT into clinical routine in the way it is desired and to replace ICA, not only for exclusion diagnostic.
1. For production of the Matrix P Plus, only one patch is used and not three as stated in the 'Materials and Methods' section. 2. In the 'Surgical Technique' section, the authors described their positioning of the valve as close to the bifurcation. This is not in accordance with AutoTissue's recommendations. It is suggested to place the valve like a homograft, which means in a more or less orthotopic position. 3. Selection of valve sizes is very problematic in this article.
Of the six explanted valves, one has been too small, three were too large and only two valves in this cohort had the appropriate size. 4. Five out of six patients had stenoses at the distal anastomosis. This has nothing to do with the tissueengineered valve but with the residual glutaraldehyde in the equine patch, which envelopes the valve. 5. The authors described 'a' dissection like 'separation of the layers between the internal and external conduit membrane, which was still blood perfused during the explantation'. This is very difficult to understand as blood between the valve and the patch will exit through the holes into the pericardial space. Hopefully, during surgery, the surgeons from Erlangen had not closed those prefabricated holes in the patch. 6. The histology shows the same pattern as with Contegra or Shellhigh valves, which means fibro-proliferative tissue at the level of the distal anastomosis. This is probably due to residual glutaraldehyde in the patch material. 7. The authors described that the outer patch remained cellfree, which is actually impossible. The outer patch is glutaraldehyde-fixed equine pericardium, which is not cell-free, only the valve within the patch is cell-free. AutoTissue is alert to the problems arising from the use of glutaraldehyde in its valved conduit and soon will bring out a conduit totally free from glutaraldehyde.
